secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gritstone bio, Inc. (—)
CIK:        0001656634
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056916
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gritstone reports Q1 cash $52.8M; GRANITE Phase 2 MSS-CRC shows favorable PFS trend (HR 0.82 overall, 0.52 high-risk)
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $52.8M as of March 31, 2024, down from $86.9M at Dec 31, 2023.
- Preliminary Phase 2 GRANITE data: PFS hazard ratio 0.82 overall (95% CI 0.34-1.67) and 0.52 in high-risk group (95% CI 0.15-1.38); mature data expected Q3 2024.
- Completed public offering in April 2024 for gross proceeds of $32.5M; appointed Stephen Webster to Board.
- R&D expenses $33.0M, G&A $8.5M for Q1 2024; collaboration & grant revenue $1.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1656634/000095017024056916/0000950170-24-056916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1656634/000095017024056916/grts-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer